A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2

2024-513445-37-00 · tracked via the Priya Life Science EU tracker

Sponsor

University Of Cologne

Sponsor type

Educational Institution

Therapeutic area

Neoplasms

Decision date

18/03/2026

Enrollment target

Sites

Austria, Germany, Denmark, Ireland, Netherlands

Condition studied

previously untreated RT, irrespective of risk factors and disease stage

Investigational medicinal product(s)

Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusionJaypirca 100 mg film-coated tabletsEPCORITAMABPREDNISOLONEEPCORITAMABVINCRISTINECYCLOPHOSPHAMIDEMabThera 100 mg concentrate for solution for infusion

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

Investigator-assessed progression-free survival (PFS) according to Lugano criteria

Endpoint detail

Overall response rate (ORR; assessed by Lugano), Complete response rate (CRR; assessed by Lugano guidelines) at the end of (combination) treatment [EO(C)T], Best response (assessed by Lugano), Undetectable minimal residual disease (uMRD) rate in peripheral blood at EO(C)T, Duration of response (DOR) according to Lugano criteria, Overall survival (OS), Time-to-next treatment (TTNT), Treatment-free survival (TFS), Proportion of patients receiving allogeneic stem cell transplantation (SCT) for consolidation

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-513445-37-00 on CTIS ↗ ← All trials in the EU